Unexpected finding points to potential way to stop macular degeneration
In a major step forward in the battle against macular degeneration, the leading cause of vision loss among the elderly, researchers at the University of Virginia School of Medicine have discovered a critical trigger for the damaging inflammation that ultimately robs millions of their sight. The finding may allow doctors to halt the inflammation early on, potentially saving patients from blindness.
“Almost 200 million people in the world have macular degeneration. If macular degeneration were a country, it would be the eighth most populated nation in the world. That’s how large a problem this is,” said Jayakrishna Ambati, MD, vice chairman for research of UVA’s Department of Ophthalmology and the founding director of UVA’s Center for Advanced Vision Science. “For the first time, we know in macular degeneration what is one of the very first events that triggers the system to get alarmed and start, to use an anthropomorphic term, hyperventilating. This overdrive of inflammation is what ultimately damages cells, and so, potentially, we have a way of interfering very early in the process.”
Potential New Treatment for Macular Degeneration
Ambati and Nagaraj Kerur, PhD, assistant professor in the Department of Ophthalmology, and their laboratories have determined that the culprit is an enzyme called cGAS. The enzyme plays an important role in the body’s immune response to infections by detecting foreign DNA. But the molecule’s newly identified role in the “dry” form of age-related macular degeneration comes as wholly unexpected.
“It’s really surprising that in macular degeneration, which, as far as we know, has nothing to do with viruses or bacteria, that cGAS is activated, and that this alarm system is turned on,” Ambati said. “This is what leads to the killing of the cells in the retina, and, ultimately, vision loss.”
The researchers noted that cGAS may be an alarm not just for pathogens but for other harmful problems that warrant responses from the immune system. The enzyme may also play important roles in conditions such as diabetes, lupus and obesity, and researchers already are working to create drugs that could inhibit its function. “Because the target we’re talking about is an enzyme, we could develop small molecules that could block it,” Kerur said. “There are many drugs already on the market that target specific enzymes, such as the statins [which are used to lower cholesterol levels.]”
The promising new lead comes as good news for researchers seeking to develop new treatments for dry macular degeneration, as clinical trials in recent years have come to dead end after dead end.
The UVA researchers expect the development of a drug to inhibit cGAS will take several years, and that drug would then need to go through extensive testing to determine its safety and effectiveness for combating macular degeneration.
The researchers also hope to develop a way to detect the levels of the enzyme in patients’ eyes. That would let them determine when best to administer a treatment that blocks cGAS. “If they have high levels of this enzyme in their eye, they might be a wonderful candidate for this sort of treatment,” Ambati said. “This is really precision medicine at the single-molecule level.”
The Latest on: Macular degeneration
- Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Boardon May 18, 2021 at 6:26 am
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company developing novel therapies for diseases related to chronic glucose imbalance, today announced the addition of Quan Dong Nguyen ...
- Bayer (BAYRY) Inks Deal to Develop Therapies for Eye Diseaseson May 18, 2021 at 5:07 am
Bayer Aktiengesellschaft ’s BAYRY wholly-owned subsidiary, BlueRock Therapeutics LP, FUJIFILM Cellular Dynamics, Inc. and Opsis Therapeutics, LLC, announced that they have entered into a strategic ...
- Clearside Biomedical Announces First Quarter 2021 Financial Results and Provides Corporate Updateon May 17, 2021 at 1:07 pm
Multiple ARVO Presentations Highlight Suprachoroidal Delivery with SCS Microinjector ® - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., May 17, 2021 (GLOBE ...
- Scotopic thresholds on dark-adapted chromatic perimetry in healthy aging and age-related macular degenerationon May 14, 2021 at 3:07 pm
To evaluate the effect of aging, intra- and intersession repeatability and regional scotopic sensitivities in healthy and age-related macular degeneration (AMD) eyes. Intra- and intersession agreement ...
- Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss ...on May 13, 2021 at 8:00 am
Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-rel ...
- Juvenile Macular Degeneration (JMD) Market By Regional Trend & Growth Forecast 2020-2030on May 12, 2021 at 11:16 pm
Selbyville, Delaware Juvenile Macular Degeneration (JMD) Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has ...
- HiltonHead Retina Specialist Surgeon Diabetic Retinopathy Macular Degenerationon May 11, 2021 at 7:00 pm
The opening of the Hilton Head Retina Institute in Hilton Head, South Carolina, has just been announced. The new retina specialist practice will be overseen by the respected ophthalmologist Dr. Baker.
- Age-Related Macular Degeneration Revisited in Nature Reviews Disease Primerson May 6, 2021 at 12:43 pm
An international collaboration of scientists publishing in Nature Reviews Disease Primers this week advocate for a new way of thinking about and finding treatments for age-related macular degeneration ...
- Age-related macular degenerationon May 6, 2021 at 2:38 am
Age-related macular degeneration (AMD) is the leading cause of severe vision loss in the developed world. This Primer describes the different stages of AMD, its epidemiology, the current understanding ...
- Stealth BioTherapeutics Showcases Data for Elamipretide in Dry Age-Related Macular Degeneration at the 2021 ARVO Annual Meetingon May 5, 2021 at 1:30 pm
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, ...
via Google News and Bing News